Overview

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Status:
RECRUITING
Trial end date:
2030-04-30
Target enrollment:
Participant gender:
Summary
A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.
Phase:
PHASE1
Details
Lead Sponsor:
JCR Pharmaceuticals Co., Ltd.